Dr. Martin Münchbach
Dr. Münchbach is senior investment advisor for BB BIOTECH VENTURES. He has invested in life science companies across all stages and types. Before becoming a venture capitalist, Dr. Münchbach gained experience in strategic marketing at Sanofi-Synthélabo. Dr. Münchbach holds a PhD in Protein Chemistry, an MSc in Biochemistry and a Master in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH), Zurich. Dr. Münchbach’s past and current board assignments include 4-Antibodies AG, Atlas Genetics Ltd, Axovan (acquired by Actelion), Glycart Biotechnologies AG (acquired by Roche), Molecular Partners AG, Optimer Pharmaceuticals Inc (now publicly listed), Opsona Therapeutics Ltd, Radius Health Inc, Sonetik AG, and Tioga Pharmaceuticals Inc.
Dr. Klaus Breiner
Dr. Breiner is senior investment advisor for BB BIOTECH VENTURES. He has invested in a broad range of life science companies. Before becoming a venture capitalist, he was a business consultant with Booz Allen & Hamilton in Zurich, and a researcher at the Swiss Federal Institute of Technology (ETH) in Zurich and at the Center for Molecular Biology in Heidelberg (ZMBH). Dr. Breiner holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in Molecular Biology from the University of Heidelberg. Dr. Breiner’s past and present board assignments include Agendia BV, AM-Pharma BV, Alpex Pharma SA, Cadence Pharmaceuticals Inc. (now publicly listed), Glycart Biotechnology AG (acquired by Roche), Natural Dental Implants AG, Orthocon Inc., and Vaximm AG.